Spectrum of Apolipoprotein AI and Apolipoprotein AII Proteoforms and Their Associations With Indices of

John T Wilkins1, Henrique S Seckler2, Jonathan Rink3

  • 1Department of Medicine (Cardiology) and Department of Preventive Medicine Northwestern University Chicago IL.

Insights

High-density lipoprotein (HDL) proteins apolipoprotein AI (apoAI) and apolipoprotein AII (apoAII) have proteoform-specific associations with cardiometabolic health. Understanding these distinct protein variants offers new insights into heart disease and diabetes risk.

Area of Science:

  • Biochemistry
  • Proteomics
  • Cardiovascular Science

Background:

  • High-density lipoproteins (HDL) contain apolipoprotein AI (apoAI) and apolipoprotein AII (apoAII), which exist as various proteoforms due to post-translational modifications.
  • The full range of apoAI and apoAII proteoforms and their impact on cardiometabolic health are not well understood.

Purpose of the Study:

  • To comprehensively characterize apoAI and apoAII proteoforms in human serum.
  • To investigate the associations between these proteoforms and cardiometabolic health indices.

Main Methods:

  • Utilized top-down proteomics on serum samples from the Coronary Artery Risk Development in Young Adults (CARDIA) study.
  • Analyzed 15 apoAI and 9 apoAII proteoforms, identifying 6 novel post-translational modifications.

Main Results:

  • Canonical apoAI associated with lower HDL cholesterol and efflux, and higher obesity and triglyceride levels.
  • Fatty-acid modified apoAI proteoforms showed positive associations with HDL cholesterol and efflux, and inverse associations with obesity and triglycerides.
  • Truncated/dimerized apoAII proteoforms were positively linked to HDL cholesterol and inversely to obesity.

Conclusions:

  • Cardiometabolic associations of apoAI and apoAII are proteoform-specific.
  • Precise characterization of apolipoprotein proteoforms enhances understanding of health and disease pathways.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
513
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
88
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
267
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
70
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
355
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
406